Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Regeneron Pharmaceuticals Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $92.73 (market cap $5.86B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13× State Street SPDR Bloomberg High Yield Bond ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg High Yield Bond ETF for 60 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| JNK | REGN | |
|---|---|---|
Market Cap | $5.86B | $76.14B |
Volume | 7,780,002 | 500,239 |
Sector | Fixed Income | Health |
52-Week High | $98.02 | $852.03 |
52-Week Low | $92.30 | $557.73 |
Typical Hold Time | 60 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $92.76, down 0.13% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key support at $92. Recent dividend distributions of $0.53 provide income, though financial ratios are unavailable. Market sentiment is influenced by rising bond yields and geopolitical tensions affecting high-yield debt markets.
Outlook remains cautious amid elevated Treasury yields and inflation concerns. The high-yield bond sector faces pressure from borrowing costs, though institutional interest persists. Key risks include interest rate volatility and economic slowdown impacting credit quality. Income-focused investors may find value in dividend yield despite market headwinds.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
